Biocatalysis is very appealing for industry because it allows the synthesis of products that are not accessible by chemical synthesis, use of alternative raw materials, lower operating costs, low fixed cost infrastructure and improved eco-efficiency [1]. Chemical biosynthesis has emerged as a valuable tool in organic chemistry that provides straightforward and efficient alternatives to traditional chemical synthesis [2]. Advances in enzyme discovery, high-throughput screening and protein engineering have substantially expanded the available biocatalysts, and consequently, many more synthetic transformations are now possible. The chemo-, regio-, diastereo-and enantio-selectivity of biocatalysts are among the properties that render them superior to chemical catalysts [3,4]. Enzymes are biodegradable and easily replaced through inexpensive and environmentally benign fermentation processes. The minimal environmental and economic burden posed by enzymes is further diminished by the potential to engineer even more active variants than can be found in nature, to optimize expression efficiencies and fermentation yields, and to immobilize and reuse these powerful catalysts. Biocatalysis has been used widely to produce chiral pharmaceutical intermediates to make small molecule drugs [5].This Special Issue discusses some of the key drivers and scientific developments that are expanding the application of biocatalysis in the pharmaceutical industry through several examples; kinetic characteristics of cofactor-enzyme complex against aldehydes giving important pharmaceutical precursors [6], cyclodextrin glucanotransferase from Thermoanaerobacter sp is able to glycosylate a ternary alchols [7,8], bi-enzymatic cascade for the synthesis of optically pure compounds [9], Sporomusa ovata used as microbial catalyst to determine whether electron uptake is hydrogen-dependent [10] and esterification of ferulate with octanol catalyzed by lipase in a solvent-free system [11]. In addition, two reviews on biocatalysis as a useful tool in asymmetric synthesis [12] and pseudokinases as suitable drug targets for the treatment of various diseases [13] give an idea about the impact of biocatalysis in drug development.The research article of Karanam et al. deals with the importance of an (R) specific carbonyl reductase from Candida parapsilosis as a biocatalyst in the reduction of ketones and keto-esters of aliphatic and aromatic aldehydes [6]. García-Arellano et al. investigated the enzymatic synthesis, using a cyclodextrin glycosyltransferase from Thermoanaerobacter sp, of novel alkyl glycoside derivatives which are used as non-ionic surface-active agents in food, cosmetic and detergent industries [7]. Chiang et al. studied the enzymatic synthesis of new isoflavone glucosides, 8-OHDe-7/8-O-β-glucoside, increasing its solubility and stability to be used in pharmaceutical and cosmeceutical applications [8]. The other paper in this Special Issue focuses on a particular application in the use of enzymatic cascades in one pot for the synthesis of ac...